학술논문

The Ashitaba (Angelica keiskei) chalcones 4-hydroxyderricin and xanthoangelol suppress melanomagenesis by targeting BRAF and PI3-K
Document Type
article
Source
Cancer Prevention Research. 11(10)
Subject
Prevention
Cancer
2.1 Biological and endogenous factors
Aetiology
Angelica
Animals
Carcinogenesis
Cell Line
Tumor
Chalcone
Drug Screening Assays
Antitumor
Humans
Melanoma
Experimental
Mice
Mice
Knockout
Mutation
PTEN Phosphohydrolase
Phosphatidylinositol 3-Kinases
Plant Extracts
Proto-Oncogene Proteins B-raf
Signal Transduction
Skin Neoplasms
Treatment Outcome
Clinical Sciences
Oncology and Carcinogenesis
Oncology & Carcinogenesis
Language
Abstract
Malignant melanoma is an aggressive tumor of the skin and still lacks effective preventive and therapeutic treatments. In melanoma, both the BRAF/MEK/ERK and PI3-K/AKT signaling pathways are constitutively activated through multiple mechanisms, which result in cell-cycle progression and prevention of apoptosis. Therefore, the development of novel strategies for targeting BRAF and PI3K are of utmost importance. In this study, we found that Ashitaba (Angelica keiskei) chalcones, 4-hydroxyderricin (4HD) and xanthoangelol (XAG), suppressed melanoma development by directly targeting both BRAFV600E and PI3K, which blocked the activation of downstream signaling. This led to the induction of G1 phase cell-cycle arrest and apoptosis in melanoma cells. Importantly, 4HD or XAG dramatically attenuated tumor incidence and volume in the BRAF-activated Pten-deficient melanoma mouse model. Our findings suggest that 4HD and XAG are promising chemopreventive or potential therapeutic agents against melanomagenesis that act by targeting both BRAF and PI3K, providing hope for rapid clinical translation. Cancer Prev Res; 11(10); 607-20. ©2018 AACR.